KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non-Current Liabilities: 2010-2024

Historic Other Non-Current Liabilities for Ionis Pharmaceuticals (IONS) over the last 10 years, with Dec 2024 value amounting to $51.9 million.

  • Ionis Pharmaceuticals' Other Non-Current Liabilities fell 94.65% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year decrease of 94.65%. This contributed to the annual value of $51.9 million for FY2024, which is 89.89% down from last year.
  • Ionis Pharmaceuticals' Other Non-Current Liabilities amounted to $51.9 million in FY2024, which was down 89.89% from $513.7 million recorded in FY2023.
  • In the past 5 years, Ionis Pharmaceuticals' Other Non-Current Liabilities registered a high of $513.7 million during FY2023, and its lowest value of $6.9 million during FY2021.
  • In the last 2 years, Ionis Pharmaceuticals' Other Non-Current Liabilities had a median value of $282.8 million in 2023 and averaged $282.8 million.
  • Data for Ionis Pharmaceuticals' Other Non-Current Liabilities shows a maximum YoY plummeted of 89.89% (in 2024) over the last 5 years.
  • Ionis Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $6.9 million in 2021, then reached $513.7 million in 2023, then plummeted by 89.89% to $51.9 million in 2024.